曹敏华

• 1:广州维力医疗器械股份有限公司

摘要(Abstract)：

紫杉醇药物球囊导管在治疗管腔狭窄疾病方面具有重要意义，其凭借将药物快速且精准地送达病变部位、抑制平滑肌细胞增殖、降低再狭窄率的优势，成为一种有效的治疗手段。优化药物配方，降低紫杉醇在输送过程中的损失，提高紫杉醇在病变部位的转载率，以及延长药物在组织内的存留时间，是紫杉醇药物球囊导管的研发核心。在药物配方中，不同剂型的紫杉醇如无定型态、晶态、脂质体、纳米粒等，可直接影响球囊表面紫杉醇的转载率及其在组织中的代谢速度。使用不同比例及不同种类的赋形剂，如亲水性、亲脂性和两亲性等，会对药物的附着性、释放速度以及在组织内的存留时间等产生不同的影响。此外，球囊装载紫杉醇药物的方式，也会影响药物球囊的临床疗效。

关键词(KeyWords)： 增生;紫杉醇;药物球囊;赋形剂

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 曹敏华

参考文献(References)：

• [1]《药物涂层球囊临床应用中国专家共识(第二版)》专家组.药物涂层球囊临床应用中国专家共识(第二版)[J].中国介入心脏病学杂志,2023,31(6):413-426.DOI:10.3969/j.issn.1004-8812.2023.06.003.
• [2]李占鲁,黄翯.紫杉醇涂层球囊的应用现状和不足以及新一代药物涂层球囊的研究进展[J].中国介入心脏病学杂志,2022,30(4):299-302.DOI:10.3969/j.issn.1004-8812.2022.04.009.
• [3]Wani MC,Taylor HL,Wall ME,et al.Plant antitumor agents.VI.Isolation and structure of taxol,a novel antileukemic and antitumor agent from Taxus brevifolia[J].J Am Chem Soc,1971,93(9):2325-2327.DOI:10.1021/ja00738a045.
• [4]Rowinsky EK,Cazenave LA,Donehower RC.Taxol:a novel investigational antimicrotubule agent[J].J Natl Cancer Inst,1990,82(15):1247-1259.DOI:10.1093/jnci/82.15.1247.
• [5]Rowinsky EK,Donehower RC.Paclitaxel(taxol)[J].N Engl J Med,1995,332(15):1004-1014.DOI:10.1056/NEJM199504133321507.
• [6]Levin AD,Vukmirovic N,Hwang CW,et al.Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel[J].Proc Natl Acad Sci U S A,2004,101(25):9463-9467.DOI:10.1073/pnas.0400918101.
• [7]Creel CJ,Lovich MA,Edelman ER.Arterial paclitaxel distribution and deposition[J].Circ Res,2000,86(8):879-884.DOI:10.1161/01.res.86.8.879.
• [8]Axel DI,Kunert W,Goggelmann C,et al.Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery[J].Circulation,1997,96(2):636-645.DOI:10.1161/01.cir.96.2.636.
• [9]Nikol S,Huehns TY,H?fling B.Molecular biology and postangioplasty restenosis[J].Atherosclerosis,1996,123(1-2):17-31.DOI:10.1016/0021-9150(96)05807-8.
• [10]Kelsch B,Scheller B,Biedermann M,et al.Dose response to Paclitaxel-coated balloon catheters in the porcine coronary overstretch and stent implantation model[J].Invest Radiol,2011,46(4):255-263.DOI:10.1097/RLI.0b013e31820577df.
• [11] Serruys PW,Sianos G,Abizaid A,et al.The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform:the Paclitaxel In-Stent Controlled Elution Study(PISCES)[J].J Am Coll Cardiol,2005,46(2):253-260.DOI:10.1016/j.jacc.2005.03.069.
• [12]Granada JF,Stenoien M,Buszman PP,et al.Mechanisms of tissue uptake and retention of paclitaxel-coated balloons:impact on neointimal proliferation and healing[J].Open Heart,2014,1(1):e000117.DOI:10.1136/openhrt-2014-000117.
• [13]Gongora CA,Shibuya M,Wessler JD,et al.Impact of paclitaxel dose on tissue pharmacokinetics and vascular healing:a comparative drug-coated balloon study in the familial hypercholesterolemic swine model of superficial femoral in-stent restenosis[J].JACC Cardiovasc Interv,2015,8(8):1115-1123.DOI:10.1016/j.jcin.2015.03.020.
• [14]Gubernator J.Active methods of drug loading into liposomes:recent strategies for stable drug entrapment and increased in vivo activity[J].Expert Opin Drug Deliv,2011,8(5):565-580.DOI:10.1517/17425247.2011.566552.
• [15] Jawale JK,Kashikar VS.An overview on nano niosomes:as an optimistic drug delivery system in targeted drug delivery[J].Journal of Pharmaceutical Research International,2022,34(34):14-25.DOI:10.9734/JPRI/2022/v34i34A36142.
• [16]Lee HI,Rhim WK,Kang EY,et al.A multilayer functionalized drug-eluting balloon for treatment of coronary artery disease[J].Pharmaceutics,2021,13(5):614.DOI:10.3390/pharmaceutics 13050614.
• [17]冯赫宣,李佩珊,刘懿萱,等.脂质体的研究与应用进展[J].药学进展,2024,48(10):725-734.DOI:10.20053/j.issn1001-5094.2024.10.002.
• [18]Hashemzadeh S,Bina F,Khounsari HM,et al.Nanotechnology in the development of cardiac stents[J].J Drug Deliv Sci Technol,2024,95:105596.DOI:10.1016/j.jddst.2024.105596.
• [19]Trepanier CM,Burke-Kleinman J,Strauss BH,et al.Less is more:developments in nanotechnology for antirestenosis therapies[J].Arterioscler Thromb Vasc Biol,2023,43(7):1096-1110.DOI:10.1161/ATVBAHA.123.318450.
• [20]Ng JCK,Toong DWY,Ow V,et al.Progress in drug-delivery systems in cardiovascular applications:stents,balloons and nanoencapsulation[J].Nano medicine(Lond),2022,17(5):325-347.DOI:10.2217/nnm-2021-0288.
• [21]Kawai K,Rahman MT,Nowicki R,et al.Efficacy and safety of dual paclitaxel and sirolimus nanoparticle-coated balloon[J].JACC Basic Transl Sci,2024,9(6):774-789.DOI:10.1016/j.jacbts.2024.02.002.
• [22]Basavarajaiah S,Athukorala S,Kalogeras K,et al.Midterm clinical outcomes from use of Sirolimus coated balloon in coronary intervention;data from real world population[J].Catheter Cardiovasc Interv,2021,98(1):57-65.DOI:10.1002/ccd.28998.
• [23]Caradu C,Webster C,Nasr B,et al.French multicentric registry on LUMINOR drug-eluting balloon for superficial femoral and popliteal arteries[J].J Vasc Surg,2025,81(3):693-703.e3.DOI:10.1016/j.jvs.2024.10.068.
• [24]Cremers B,Biedermann M,Mahnkopf D,et al.Comparison of two different paclitaxel-coated balloon catheters in the porcine coronary restenosis model[J].Clin Res Cardiol,2009,98(5):325-330.DOI:10.1007/s00392-009-0008-2.
• [25]Afari ME,Granada JF.Mechanisms of action in drug-coated balloons[J].Endovascular Today,2012,11:53-58.DOI:10.1007/s11886-018-1025-4.
• [26]W?hrle J,Zadura M,M?bius-Winkler S,et al.SeQuent Please World Wide Registry:clinical results of SeQuent please paclitaxel-coated balloon angioplasty in a large-scale,pro spective registry study[J].J Am Coll Cardiol,2012,60(18):1733-1738.DOI:10.1016/j.jacc.2012.07.040.
• [27]Krishnan P,Faries P,Niazi K,et al.Stellarex drug-coated balloon for treatment of femoropopliteal disease:twelve-month outcomes from the randomized ILLUMENATE pivotal and pharmacokinetic studies[J].Circulation,2017,136(12):1102-1113.DOI:10.116 1/CIRCULATIONAHA.117.028893.
• [28]Waksman R,Serra A,Loh JP,et al.Drug-coated balloons for de novo coronary lesions:results from the ValentinesⅡtrial[J].Euro Intervention,2013,9(5):613-619.DOI:10.4244/EIJV9I5A98.
• [29]Woolford S,Tran M,Yoda C,et al.Studying the effect of drug-toexcipient ratio on drug release profile for drug coated balloons[J].Int J Pharm,2022,620:121749.DOI:10.1016/j.ijpharm.2022.121749.
• [30]Fuj ihara M,Takahara M,Soga Y,et al.Application of first-generation high-and low-dose drug-coated balloons to the femoropopliteal artery disease:a sub-analysis of the POPCORN registry[J].CVIR Endovasc,2023,6(1):41.DOI:10.1186/s42155-023-00390-x.
• [31] Gandhi PJ,Murthy ZVP.Investigation of different drug deposition techniques on drug releasing properties of cardiovascular drug coated balloons[J].Industrial&Engineering Chemistry Research,2012,51(33):10800-10823.DOI:10.1021/ie3006676.
• [32]Fuglsby K,Anderson JA,Engebretson D,et al.Development of an automated micropipette coating method for drug-coated balloons[J].J Biomed Mater Res B Appl Biomater,2020,108(5):2258-2275.DOI:10.1002/jbm.b.34563.
• [33]Jun EJ,Shin ES,Yuan SL,et al.Comparison of 2 different paclitaxel-coated balloons in coronary in-stent restenosis:a randomized controlled trial[J].JACC Asia,2022,2(2):170-179.DOI:10.1016/j.j acasi.2021.11.015.
• [34]Kaule S,Minrath I,Stein F,et al.Correlating coating characteristics with the performance of drug-coated balloons-a comparative in vitro investigation of own established hydrogeland ionic liquid-based coating matrices[J].PLoS One,2015,10(3):e0116080.DOI:10.1371/journal.pone.0116080.
• [35]Woolford S,Tran M,Yoda C,et al.Studying the effect of drugto-excipient ratio on drug release profile for drug coated balloons[J].Int J Pharm,2022,620:121749.DOI:10.1016/j.ijpharm.2022.121749.
• [36]Speck U,Scheller B,Abramjuk C,et al.Inhibition of restenosis in stented porcine coronary arteries:uptake of paclitaxel from angiographic contrast media[J].Invest Radiol,2004,39(3):182-186.DOI:10.1097/01.rli.0000116125.96544.64.
• [37]Berg MC,Kolodziej H,Cremers B,et al.Drug-coated angioplasty balloon catheters:coating compositions and methods[J].Advanced Engineering Materials,2012,14(3):B45-B50.DOI:10.1002/adem.201180067.
• [38]Xiong GM,Ang H,Lin J,et al.Materials technology in drug eluting balloons:current and future perspectives[J].J Control Release,2016,239:92-106.DOI:10.1016/j.jconrel.2016.08.018.
• [39]Granada JF,Tellez A,Baumbach WR,et al.In vivo delivery and long-term tissue retention of nano-encapsulated sirolimus using a novel porous balloon angioplasty system[J].Euro Intervention,2016,12(6):740-747.DOI:10.4244/EIJY15M10_01.
• [40]Oberhoff M,Kunert W,Herdeg C,et al.Inhibition of smooth muscle cell proliferation after local drug delivery of the antimitotic drug paclitaxel using a porous balloon catheter[J].Basic Res Cardiol,2001,96(3):275-282.DOI:10.1007/s003950170058.
• [41]Herdeg C,Oberhoff M,Baumbach A,et al.Local paclitaxel delivery for the prevention of restenosis:biological effects and efficacy in vivo[J].J Am Coll Cardiol,2000,35(7):1969-1976.DOI:10.1016/s0735-1097(00)00614-8.